Management of inherited von Willebrand disease in 2007

References

• Castaman G., Federici A. B., Rodeghiero F., Mannnucci P. M. Von Willebrand's disease in the year 2003: towards the complete identification of gene defects for correct diagnosis and treatment. Haematologica 2003; 88: 94–108
   PubMed Web of Science ®Google Scholar
• Lee C. A., Kessler C. M., editors. Proceedings of a Nordic von Willebrand symposium. Haemophilia 1999; 5(suppl 2)
   Google Scholar
• Zimmerman T. S., Ratnoff O. D., Powell A. E. Immunologic differentiations of classic hemophilia (Facor VIII Deficiency) and von Willebrand's disease. J Clin Invest 1971; 50: 244–54
   PubMed Web of Science ®Google Scholar
• Federici A. B., Berntorp E., Lee C. A. The 80th Anniversary of von Willebrand Disease: History, Management, Research. Haemophilia 2006; 12: 563–572
   Google Scholar
• Ruggeri Z. M. Structure of von Willebrand factor and its function in platelet adhesion and thrombus formation. Best Pract Res Clin Haematol 2001; 14: 257–79
   PubMed Web of Science ®Google Scholar
• Mancuso D. J., Tuley E. A., Westfield L. A., Lester‐Mancuso T. I., Le Beau M. M., Sorace J. M., et al. Human von Willebrand factor gene and pseudogene: structural analysis and differentiation by polymerase chain reaction. Biochemistry 1991; 30: 253–69
   PubMed Web of Science ®Google Scholar
• Goodeve A., Eikenboom J. C. J., Ginsburg D., Hilbert L., Mazurier C., Peake I. R., et al. A standard nomenclature for von Willebrand factor gene mutations and polymorphisms. On behalf of the ISTH SSC Subcommittee on von Willebrand factor. Thromb Haemost 2001; 85: 929–31
   Google Scholar
• Vlot A. J., Koppelman S. J., Bouma B. N., Sixma J. J. Factor VIII and von Willebrand Factor. Thromb Haemost 1998; 79: 456–65
   PubMed Web of Science ®Google Scholar
• Mazurier C., Rodeghiero F. Recommended abbreviations for von Willebrand factor and its activities. Thromb Haemost 2001; 85: 929–31
   Google Scholar
• Sadler J. E. A revised classification of von Willebrand disease. For the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 1994; 71: 520–3
   PubMed Web of Science ®Google Scholar
• Sadler J. E., Budde U., Eikenboom J. C. J., Favaloro E. J., Hill F. G., Holmberg L., et al. Update on the pathophysiology and classification of von Willebrand disease. A report of the Subcommittee on von Willebrand factor. J Thromb Haemost 2006; 4: 2103–14
   PubMed Web of Science ®Google Scholar
• Federici A. B., Castaman G., Mannucci P. M. Guidelines for the diagnosis and management of VWD in Italy. Haemophilia 2002; 8: 607–21
   PubMed Web of Science ®Google Scholar
• Federici A. B. Clinical diagnosis of von Willebrand disease. Haemophilia 2004; 10: 169–76
   PubMed Web of Science ®Google Scholar
• Mazurier C., Hilbert L. Type 2 N von Willebrand disease. Current Hematol Rep 2005; 4: 350–8
   Google Scholar
• Gill J. C., Endres‐Brooks J., Bauer P. J., Marks W. J., Montgomery R. R. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood 1987; 69: 1691–5
   PubMed Web of Science ®Google Scholar
• Kunicki T. J., Federici A. B., Salomon D. R., Koziol J. A., Head S. R., Mondala T. S., et al. An association of candidate gene haplotypes and bleeding severity in Von Willebrand Disease (VWD) type 1 pedigrees. Blood 2004; 104: 2359–67
   PubMed Web of Science ®Google Scholar
• Silwer J. von Willebrand's disease in Sweden. Acta Paediat Scand 1973; 238: 1–159
   Google Scholar
• Lak M., Peyvandi F., Mannucci P. M. Clinical manifestations and complications of childbirth and replacement therapy in 348 Iranian patients with type 3 von Willebrand disease. Br J Haematol 2000; 111: 1223–9
   Google Scholar
• Rodeghiero F., Castaman G., Tosetto A., Battle J., Baudo F., Cappelletti A., et al. The discriminant power of bleeding history for the diagnosis of von Willebrand disease type 1: an international multicenter study. J Thromb Hemost 2005; 3: 2619–26
   Google Scholar
• Tosetto A., Rodeghiero F., Castaman G., Goodeve A., Federici A. B., Battle J., et al. A quantitative analysis of bleeding symptoms in type 1 of von Willebrand disease: results from a multicenter European Study (MCMDM‐1VWD). J Thromb Hemost 2006; 4: 774–82
   Google Scholar
• Mannucci P. M., Lombardi R., Bader R., Vianello L., Federici A. B., Solinas S., et al. Heterogeneity of type I von Willebrand's disease: evidence for a subgroup with an abnormal von Willebrand Factor. Blood 1985; 66: 796–802
   PubMed Web of Science ®Google Scholar
• Cattaneo M., Federici A. B., Lecchi A., Agati B., Lombardi R., Stabile F., et al. Evaluation of the PFA‐100 System in the diagnosis and therapeutic monitoring of patients with von Willebrand Disease. Thromb Haemost 1999; 82: 35–39
   PubMed Web of Science ®Google Scholar
• Favaloro E. J. Collagen binding assay for von Willebrand factor (VWF:CBA): detection of von Willebrands disease (VWD), and discrimination of VWD subtypes, depends on collagen source. Thromb Haemost 2000; 83: 127–35
   PubMed Web of Science ®Google Scholar
• Federici A. B., Canciani M. T., Forza I., Cozzi G. Ristocetin cofactor and collagen binding activities normalized to antigen levels for a rapid diagnosis of type 2 von Willebrand disease: single center comparison of four different assays. Thromb Haemost 2000; 84: 1127–8
   PubMed Web of Science ®Google Scholar
• Mannucci P. M., Federici A. B. Antibodies to von Willebrand factor in von Willebrand disease. Adv Exp Med Biol 1995; 386: 87–92
   Google Scholar
• Meyer D., Fressinaud E., Hilbert L., Ribba A. S., Lavergne J. M., Mazurier C. Type 2 von Willebrand disease causing defective von Willebrand factor‐dependent platelet function. Best Pract Res Clin Haematol 2001; 14: 349–64
   Google Scholar
• Schneppenheim R., Federici A. B., Budde U., Castaman G., Drewke E., Mannucci P. M., et al. Von Willebrand disease type 2 M “Vicenza” in Italian and German patients: identification of the first candidate mutation (G3864A; R1205H) in 8 families. Thromb Haemost 2000; 83: 136–40
   Google Scholar
• Castaman G., Missiaglia E., Federici A. B., Schneppenheim R., Rodeghiero F. An additional candidate mutation (G2470A; M740I) in the original families with von Willebrand disease type 2 M Vicenza and the G3864A (R1205H) mutation. Thromb Haemost 2000; 84: 350–1
   Google Scholar
• Goodeve A., Eikenboom J., Castaman G., Rodeghiero F., Federici A. B., Battle J., et al. Phenotype and genotyoe of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand disease. Blood 2007; 109: 112–121
   PubMed Web of Science ®Google Scholar
• James P. D., Notley C., Hegadorn C., Leggo J., Tuttle A., Tinlin S., et al. The mutational spectrum of type 1 von Willebrand disease: results from a Canadian cohort study. Blood 2007; 109: 145–54
   PubMed Web of Science ®Google Scholar
• Shelton‐Inloes B. B., Chebab F. F., Mannucci P. M., Federici A. B., Sadler J. E. Gene deletion correlates with the 21 development of alloantibodies in von Willebrand disease. J Clin Invest 1987; 79: 1459–65
   PubMed Web of Science ®Google Scholar
• Mannucci P. M., Tamaro G., Narchi G., Candotti G., Federici A., Altieri D., et al. Life‐threatening reaction to factor VIII concentrate in a patient with severe von Willebrand disease and alloantibodies to von Willebrand Factor. Eur J Haematol 1987; 39: 467–70
   PubMed Web of Science ®Google Scholar
• Eikenboom J. C. J. Congenital von Willebrand disease type 3: clinical manifestations, pathophysiology and molecular biology. Best Pract Res Clin Haematol 2001; 14: 365–79
   PubMed Web of Science ®Google Scholar
• Baronciani L., Cozzi G., Canciani M. T., Peyvandi F., Srivastava A., Federici A. B., et al. Molecular Characterization of a multiethnic Group of 21 Patients with type 3 von Willebrand Disease. Thromb Haemost 2000; 84: 536–40
   Google Scholar
• Schneppenheim R., Castaman G., Federici A. B., Kreuz W., Marschalek R., Oldenburg J., et al. A commom 253‐kb deletion involving VWF and TMEM16B in German and Italian patients with severe von Willebrand disease type 3. J Thromb Haemost 2007; 5: 722–8
   Google Scholar
• Mannucci P. M. Treatment of von Willebrand disease. N Eng J Med 2004; 351: 683–94
   PubMed Web of Science ®Google Scholar
• Federici A. B., Mazurier C., Berntorp E., Lee C. A., Sharrer I., Goudemand J., et al. Biological response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study. Blood 2004; 103: 2032–38
   PubMed Web of Science ®Google Scholar
• Mannucci P. M., Bettega D., Cattaneo M. Consistency of responses to repeated DDAVP infusions in patients with von Willebrand disease and haemophilia A. Br J Haematol 1992; 82: 87–93
   PubMed Web of Science ®Google Scholar
• Smith T. J., Gill J. C., Ambruso D. R. Hathaway WE. Hyponatremia and seizures in young children given DDAVP. Am J Hematol 1989; 31: 199–202
   PubMed Web of Science ®Google Scholar
• Bond L., Bevin D. Myocardial infarction in a patient with hemophilia A treated with DDAVP. N Engl J Med 1988; 318: 121
   PubMed Web of Science ®Google Scholar
• Byrnes J. J., Larcada A., Moake J. L. Thrombosis following desmopressin for uremic bleeding. Am J Hematol 1988; 28: 63–5
   Google Scholar
• Federici A. B. Management of von Willebrand disease with factor VIII/von Willebrand factor concentrates: results from current studies and surveys. Blood Coag Fibrin 2005; 16: S17–21
   PubMedGoogle Scholar
• Borel‐Derlon A., Federici A. B., Roussel‐Robert V., Goudemand J., Lee C. A., Sharrer I., et al. Treatment of severe von Willebrand disease with a high‐purity von Willebrand factor concentrate (Wilfactin): a prospective study on 50 patients. J Thromb Haemost 2007; 5: 1115–24
   PubMed Web of Science ®Google Scholar
• Mannucci P. M. Venous thromboembolism in von Willebrand disease. Thromb Haemost 2002; 88: 378–9
   PubMed Web of Science ®Google Scholar
• Bergamaschini L., Mannucci P. M., Federici A. B., Coppola R., Guzzoni S., Agostoni A. Posttransfusion anaphylactic reaction in a patient with severe von Willebrand disease: role of complement and alloantibodies to von Willebrand factor. J Lab Clin Med 1995; 125: 348–55
   PubMed Web of Science ®Google Scholar
• Ciavarella N., Schiavoni M., Valenzano E., Mangini F., Inchingolo F. Use of recombinant factor VIIa (Novoseven) in the treatment of two patients with type III von Willebrand disease and an inhibitor against von Willebrand factor. Haemostasis 1996; 26: 150–4
   PubMedGoogle Scholar
• Boyer‐Neumann C., Dreyfus M., Wolf M., Veyradier A., Meyer D. Multi‐therapeutic approach to manage delivery in an alloimmunized patient with type 3 von Willebrand disease. J Thromb Haemost 2003; 1: 190–2
   PubMed Web of Science ®Google Scholar
• Berntorp E., Petrini P. Long‐term prophylaxis in von Willebrand disease. Blood Coag Fibrin 2005; 16: S23–6
   PubMedGoogle Scholar
• Federici A. B., Gianniello F., Canciani M. T., Mannucci P. M. Secondary long‐term prophylaxis in severe patients with von Willebrand disease: an Italian cohort study. Blood 2005; 106: 507a, abstract 1782
   Google Scholar